Encompass Health
EHC
$122.54
+0.05%
Encompass Health Corporation is the largest owner and operator of inpatient rehabilitation hospitals in the United States, providing specialized post-acute care to patients recovering from strokes, neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations through a nationwide network of facilities. As the clear market leader in inpatient rehabilitation, the company operates in a highly regulated, capital-intensive niche of the healthcare sector with significant barriers to entry, including certificate-of-need requirements in many states and deep payer relationships. The current investor narrative centers on the company's consistent double-digit revenue growth, expanding margins, and disciplined capital deployment into new hospital beds and de novo facilities, which has driven a strong multi-quarter earnings beat cadence. Recent attention has focused on the sustainability of Medicare reimbursement rates, the company's ability to pass through labor cost inflation, and its ongoing share repurchase and dividend program, which management has continued to prioritize alongside growth capex.…
EHC
Encompass Health
$122.54
Related headlines
EHC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Encompass Health's 12-month outlook, with a consensus price target around $148.17 and implied upside of +20.9% versus the current price.
Average Target
$148.17
0 analysts
Implied Upside
+20.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$140 - $155
Analyst target range
Encompass Health is covered by 12 analysts, with a consensus recommendation of "strong buy" and a recommendation mean of 1.08 (on a scale where 1 is a strong buy and 5 is a strong sell). The average target price is $148.17, which implies a 23.7% upside from the current price of $119.80. The consensus is overwhelmingly bullish, with no sell ratings and a tight distribution of targets, indicating strong conviction among analysts. The estimated EPS average of $9.26 for the next fiscal year, combined with the forward PE of 17.94x, suggests that analysts expect earnings growth of approximately 15-20% year-over-year, driven by revenue growth and margin expansion. The target price range is relatively tight, from a low of $140.00 to a high of $155.00, representing a spread of just 10.7% around the average. The low target of $140 implies a 16.9% upside and likely assumes modest multiple expansion and steady execution on the company's growth pipeline, while the high target of $155 implies a 29.4% upside and may price in accelerating revenue growth from de novo hospital openings, favorable reimbursement updates, or a re-rating of the stock's PE multiple toward the higher end of its historical range. The tight spread signals high analyst conviction and low uncertainty about the company's near-term prospects, which is consistent with the stable, recurring nature of its revenue and the visibility provided by its Medicare reimbursement framework. Recent institutional ratings show a pattern of reiterations rather than upgrades or downgrades, with TD Cowen, Truist Securities, and UBS all maintaining Buy ratings in August 2026, and Barclays maintaining an Overweight rating. This stability in ratings suggests that analysts are comfortable with their estimates and see no near-term catalysts that would materially change their outlook, which is typical for a mature, cash-generative healthcare operator with a predictable growth trajectory.
Drowning in data?
Find the real signal!
Bulls vs Bears: EHC Investment Factors
The bull case for Encompass Health rests on its consistent revenue growth, margin expansion, strong analyst support, and attractive valuation relative to growth and peers. The bear case centers on Medicare concentration, leverage, and near-term technical weakness. Currently, the bull evidence is stronger: eight consecutive quarters of revenue growth, a PEG of 0.78, and a 23.7% upside to analyst targets outweigh the risks. The single most important tension is the sustainability of Medicare reimbursement rates—any adverse regulatory change could quickly erode the investment thesis. How this resolves will likely determine whether the stock breaks above $128 or corrects toward $115 support.
Bullish
- Consistent double-digit revenue growth: Q2 2026 revenue grew 9.58% YoY to $1.597 billion, marking the eighth consecutive quarter of YoY increases. The sequential trend from $1.455 billion in Q1 2025 to $1.597 billion in Q2 2026 demonstrates durable demand for inpatient rehabilitation services.
- Strong analyst consensus and upside: All 12 analysts rate EHC a 'strong buy' with a mean recommendation of 1.08 and an average target price of $148.17, implying 23.7% upside from $119.80. The tight target range ($140-$155) signals high conviction in the growth story.
- Undervalued relative to growth and peers: The forward PE of 17.94x and PEG ratio of 0.78 suggest the stock is undervalued given expected EPS growth of ~15-20%. The PS ratio of 1.80x is well below the healthcare facilities sector average of 2.5-3.0x, and EV/EBITDA of 9.46x is below the industry range of 11-13x.
- Expanding margins and high ROE: Operating margin expanded from 16.49% in Q3 2025 to 18.05% in Q2 2026, while net margin improved to 9.63% from 8.60% in Q4 2024. ROE of 23.22% and ROA of 9.80% demonstrate efficient capital deployment despite a capital-intensive model.
Bearish
- Medicare reimbursement concentration risk: Medicare accounted for $1.048 billion, or 65.6% of Q2 2026 revenue, exposing the company to regulatory changes in inpatient rehabilitation facility payment rates. Any cut to Medicare reimbursement could significantly pressure revenue and margins.
- Elevated leverage and capital intensity: Debt-to-equity of 1.11 and a current ratio of 1.08 indicate moderate leverage and limited liquidity buffer. Q2 2026 capex of $220.3 million consumed most of operating cash flow of $282.6 million, leaving little room for unexpected expenses.
- Near-term momentum divergence: The stock has pulled back 6.4% from its August 2026 high of $127.99, with a 1-month decline of 1.14% versus a 3-month gain of 12.53%. This short-term weakness and relative underperformance vs. SPY (-1.73% over 1 month) suggest waning buying pressure.
- Labor cost inflation pressure: Despite margin expansion, wage inflation in the healthcare labor market remains a persistent headwind. Total operating expenses rose to $1.309 billion in Q2 2026 from $1.198 billion in Q2 2025, up 9.3% YoY, outpacing revenue growth of 9.58% only slightly.
EHC Technical Analysis
Encompass Health is in a sustained medium-term uptrend that has recently stalled, with the stock trading at $119.80, roughly 70.3% of its 52-week range (52-week low of $92.77, high of $127.99). The 1-year price change of -3.04% masks a sharp recovery from the April 2026 lows near $100, as the stock has rallied 23.01% over the past six months and 12.63% year-to-date, indicating that the longer-term trend has shifted from consolidation to accumulation. At 93.6% of its 52-week high, the stock is positioned near the upper end of its range, which signals strong momentum but also raises the risk of overextension and profit-taking. Recent momentum has decelerated, with the 1-month change at -1.14% versus the 3-month change of +12.53%, creating a short-term divergence from the medium-term uptrend. This pullback of roughly 6.4% from the August 2026 high of $127.99 appears to be a consolidation phase rather than a trend reversal, especially given the stock's relative strength of +9.19% versus SPY over three months. However, the 1-month relative strength of -1.73% versus SPY suggests the stock is underperforming the broader market in the near term, which could signal waning near-term buying pressure. Key technical support lies at the 52-week low of $92.77, with a more immediate support zone around the $115-$117 area (the July 2026 breakout level), while resistance is firmly established at the 52-week high of $127.99. A breakout above $128 would likely require a fundamental catalyst, such as a strong Q3 earnings beat or favorable reimbursement news, and could open the door to a new leg higher; conversely, a breakdown below $115 would signal a deeper correction toward the $105-$110 range. With a beta of 0.608, the stock is approximately 39% less volatile than the broader market, making it a relatively defensive holding; this low beta implies that position sizing can be larger for risk-parity portfolios, but it also means the stock may lag in strong bull markets.
Beta
0.60
0.60x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$93-$128
Price range past year
Annual Return
-1.5%
Cumulative gain past year
| Period | EHC Return | S&P 500 |
|---|---|---|
| 1m | +1.7% | +1.0% |
| 3m | +11.2% | +2.5% |
| 6m | +14.3% | +13.9% |
| 1y | -1.5% | +15.0% |
| ytd | +15.2% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EHC Fundamental Analysis
Encompass Health's revenue trajectory remains robust, with Q2 2026 revenue of $1.597 billion representing 9.58% year-over-year growth from $1.458 billion in Q2 2025. The multi-quarter trend shows consistent sequential growth, with revenue rising from $1.455 billion in Q1 2025 to $1.597 billion in Q2 2026, and the company has now posted eight consecutive quarters of year-over-year revenue increases. The revenue mix is heavily concentrated in Medicare, which contributed $1.048 billion (approximately 65.6% of total revenue), followed by Managed Care at $171.3 million (10.7%), Medicaid at $49.6 million (3.1%), and smaller contributions from patients and workers' compensation. This payer concentration is a double-edged sword: it provides stable, recurring revenue but exposes the company to regulatory and reimbursement risks, particularly any changes to Medicare's inpatient rehabilitation facility payment rates. Profitability is strong and improving, with Q2 2026 net income of $153.9 million and a net margin of 9.63%, up from 9.75% in Q2 2025 and 8.60% in Q4 2024. Gross margin, reported at 100% in Q2 2026 due to the company's classification of cost of revenue, is not directly comparable to traditional gross margin metrics, but the operating margin of 18.05% and EBITDA margin of 24.09% provide a clearer picture of profitability. The operating margin has expanded from 16.49% in Q3 2025 to 18.05% in Q2 2026, driven by operating leverage on higher patient volumes and effective cost management, despite wage inflation in the healthcare labor market. The balance sheet is moderately leveraged, with a debt-to-equity ratio of 1.11 and a current ratio of 1.08, indicating adequate short-term liquidity but limited financial flexibility. Free cash flow on a trailing twelve-month basis is $413.4 million, which covers the company's dividend payments of approximately $75 million annually and share repurchases, but capital expenditures remain elevated at $220.3 million in Q2 2026 alone as the company invests in new hospital construction and bed expansions. The return on equity of 23.22% is impressive for a capital-intensive healthcare operator, reflecting efficient use of debt to fund growth, while the return on assets of 9.80% demonstrates strong operational efficiency. The company's cash flow from operations was $282.6 million in Q2 2026, down from $313.1 million in Q1 2026, but still sufficient to fund its $220.3 million in capital expenditures and $18.9 million in dividend payments, with the remainder used for debt repayment and share repurchases.
Quarterly Revenue
$1.6B
2026-06
Revenue YoY Growth
+9.6%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$413399999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EHC Overvalued?
With positive net income of $153.9 million in Q2 2026 and trailing twelve-month earnings, the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 18.89x and a forward PE of 17.94x, with the modest 5% gap between the two suggesting that the market is pricing in moderate earnings growth rather than explosive expansion. The forward PE of 17.94x is based on estimated EPS of $9.26 for the next fiscal year, which implies a price-to-earnings growth (PEG) ratio of 0.78, indicating that the stock may be undervalued relative to its expected growth rate. Compared to the broader healthcare sector, where the average PE for medical care facilities typically ranges between 18x and 22x, Encompass Health's trailing PE of 18.89x is roughly in line with the industry average, representing neither a significant premium nor a discount. However, the company's PS ratio of 1.80x is notably lower than the sector average of approximately 2.5x to 3.0x for healthcare facilities, suggesting that the stock is undervalued on a revenue basis. The EV/EBITDA of 9.46x is also below the industry average of 11x to 13x, which may reflect the market's concern about the company's debt load and capital intensity. On a historical basis, the current PE of 18.89x is near the middle of the stock's five-year range, which has fluctuated between approximately 12x and 25x. The PS ratio of 1.80x is at the low end of its historical range, which has ranged from 1.5x to 8.6x over the past five years, suggesting that the stock is trading at a discount to its own history on a revenue basis. This could represent a value opportunity if the company continues to grow revenue and expand margins, or it could signal that the market is pricing in slower growth or higher risk. The dividend yield of 0.67% is modest but sustainable, with a payout ratio of just 12.56%, leaving ample room for continued dividend increases and share repurchases.
PE
18.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Encompass Health faces financial and operational risks primarily from its Medicare concentration and capital intensity. Medicare represents 65.6% of revenue ($1.048 billion in Q2 2026), making the company highly vulnerable to reimbursement rate cuts. Additionally, debt-to-equity of 1.11 and a current ratio of 1.08 indicate moderate leverage and tight liquidity. Capital expenditures are substantial at $220.3 million in Q2 2026 alone, consuming most of operating cash flow of $282.6 million, which limits financial flexibility and could strain the balance sheet if cash flow declines.
Market and competitive risks include valuation compression and regulatory headwinds. The stock trades at a forward PE of 17.94x, in line with the sector average, but its PS ratio of 1.80x is below peers, which may reflect concerns about growth sustainability. With a beta of 0.608, EHC is less sensitive to market swings, but sector rotation away from healthcare could still pressure the multiple. Recent news highlights the dividend declaration, but no major competitive threats have emerged; however, any change in Medicare payment policies or increased competition from other post-acute care providers could impact volumes and pricing.
The worst-case scenario would involve a significant cut to Medicare reimbursement rates combined with rising labor costs, compressing margins and slowing growth. This could drive the stock down to its 52-week low of $92.77, representing a 22.6% decline from the current price of $119.80. The analyst low target of $140 is above the current price, but in a severe downturn, the stock could test the 52-week low. Investors could lose approximately 22.6% in this adverse scenario, and if the decline accelerates, the maximum drawdown of 26.22% (from recent highs) suggests a potential loss of up to 26% from peak levels.
